BBIO vs BCDA

BridgeBio Pharma, Inc. vs BioCardia, Inc. — Valuation Comparison 2026

BBIO

Biotechnology
BridgeBio Pharma, Inc.
Quality
6.5
out of 10
Value Trap
18
SAFE
Price
$68.45
Last close
Models
8/13
Active
VS

BCDA

Biotechnology
BioCardia, Inc.
Quality
4.4
out of 10
Value Trap
40
WARN
Price
$0.92
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType BBIO Fair ValueBBIO Upside BCDA Fair ValueBCDA Upside
Bayesian DCF Intrinsic $20.19 -70.5% $0.27 -70.6%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.52 +66.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $63.52 -13.3% $0.84 -24.5%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BBIO vs BCDA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BBIO vs BCDA — Which Stock Is More Undervalued?

BBIO scores higher with a 6.5/10 quality rating vs BCDA's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BridgeBio Pharma, Inc. (BBIO) and BioCardia, Inc. (BCDA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BBIO currently trades at $68.45 with a QOC of 6.5/10, while BCDA trades at $0.92 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).